Loading clinical trials...
Loading clinical trials...
A Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Effect of Tralokinumab on Vaccine Antibody Responses in Adults With Moderate-to-severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Conditions
Interventions
Tralokinumab
Placebo
+2 more
Locations
51
United States
Leo Pharma Investigational Site
Fort Smith, Arkansas, United States
LEO Pharma Investigational Site
Bakersfield, California, United States
Leo Pharma Investigational Site
Beverly Hills, California, United States
Leo Pharma Investigational Site
Fountain Valley, California, United States
Leo Pharma Investigational Site
Los Angeles, California, United States
Leo Pharma Investigational Site
Los Angeles, California, United States
Start Date
July 13, 2018
Primary Completion Date
September 17, 2019
Completion Date
November 22, 2019
Last Updated
March 11, 2025
NCT07262983
NCT06389136
NCT06342713
NCT07223697
NCT07290803
NCT07265479
Lead Sponsor
LEO Pharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions